Managing transplant-eligible NDMM patients
Module 2 focuses on managing transplant-eligible (Te) patients with NDMM, with particular attention to high-risk disease. It covers the 2025 IMS-IMWG definition of high-risk multiple myeloma and the main high-risk subgroups (renal impairment, extramedullary disease and high-risk cytogenetics), and works through induction, ASCT and tandem ASCT, consolidation, maintenance and supportive care. After this module you will be able to evaluate treatment strategies for difficult-to-treat patients, compare single versus tandem ASCT, assess the role of consolidation therapy, and analyse maintenance regimens and optimal treatment duration.
Scientific Expert Panel
Gustav Mathiasen,
Zealand University Hospital Roskilde,
Department of Hematology,
Denmark
Dr. Ville Varmavuo,
hematologist, Senior Medical Officer in Charge of Research and Training,
Kymenlaakson hyvinvointialue,
Finland
Accreditation
Accreditation information:
TBD
Obtain CME points
To obtain CME points, you must complete both modules and answer at least 70% of the questions in the final test correctly. If you have a lower score, you can retake the final test twice more. You can pause the e-learning and then resume where you paused.
